The Sidney Kimmel Comprehensive Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
570
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (513 trials with phase data)• Click on a phase to view related trials
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: Luteinizing hormone-releasing hormone (LHRH) analogue
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-08-27
- Target Recruit Count
- 60
- Registration Number
- NCT07142551
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
DK222 Study at Hopkins
- Conditions
- Non-Small Cell Lung CancerUrothelial Cancer
- Interventions
- Drug: [18F]DK222 radiotracer
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-08-24
- Target Recruit Count
- 6
- Registration Number
- NCT07140315
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Pediatric Radiation Therapy Registry
- Conditions
- SarcomaPediatric Brain Tumors
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Target Recruit Count
- 5000
- Registration Number
- NCT07129317
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
- Conditions
- Chronic Myelomonocytic LeukemiaChronic Neutrophilic LeukemiaMyelodysplastic SyndromesMyeloproliferative Overlap Neoplasms
- Interventions
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Target Recruit Count
- 18
- Registration Number
- NCT07071155
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
- Conditions
- Renal Cell Carcinoma (Kidney Cancer)
- Interventions
- Drug: 111In-XYIMSR-01
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-23
- Target Recruit Count
- 6
- Registration Number
- NCT07062549
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 114
- Next
News
Breakthrough Study Reveals Hidden Cancer Cells in 42% of Ovarian Cancer Patients in Clinical Remission
A multi-institutional study found that 42% of ovarian cancer patients who achieved clinical remission after first-line therapy still harbored minimal residual disease (MRD) detectable through second-look laparoscopy.